Thu KL - Search Results

1

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer.

Clermont PL, Crea F, Chiang YT, Lin D, Zhang A, Wang JZ, Parolia A, Wu R, Xue H, Wang Y, Ding J, Thu KL, Lam WL, Shah SP, Collins CC, Wang Y, Helgason CD. Clermont PL, et al. Among authors: thu kl. Clin Epigenetics. 2016 Feb 12;8:16. doi: 10.1186/s13148-016-0182-9. eCollection 2016. Clin Epigenetics. 2016. PMID: 26877821 Free PMC article.

2

Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role.

Clermont PL, Sun L, Crea F, Thu KL, Zhang A, Parolia A, Lam WL, Helgason CD. Clermont PL, et al. Among authors: thu kl. Br J Cancer. 2014 Oct 14;111(8):1663-72. doi: 10.1038/bjc.2014.474. Epub 2014 Sep 16. Br J Cancer. 2014. PMID: 25225902 Free PMC article.

3

Polycomb-mediated silencing in neuroendocrine prostate cancer.

Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Collins CC, Wang Y, Helgason CD. Clermont PL, et al. Among authors: thu kl. Clin Epigenetics. 2015 Apr 3;7(1):40. doi: 10.1186/s13148-015-0074-4. eCollection 2015. Clin Epigenetics. 2015. PMID: 25859291 Free PMC article.

4

Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.

Coe BP, Thu KL, Aviel-Ronen S, Vucic EA, Gazdar AF, Lam S, Tsao MS, Lam WL. Coe BP, et al. Among authors: thu kl. PLoS One. 2013 Aug 15;8(8):e71670. doi: 10.1371/journal.pone.0071670. eCollection 2013. PLoS One. 2013. PMID: 23967231 Free PMC article.

5

In response.

Hubaux R, Thu KL, Lam WL, Alex A. Hubaux R, et al. Among authors: thu kl. J Thorac Oncol. 2013 Nov;8(11):e103-4. doi: 10.1097/01.JTO.0000435739.64803.99. J Thorac Oncol. 2013. PMID: 24128723 Free PMC article. No abstract available.

6

Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma.

Lockwood WW, Thu KL, Lin L, Pikor LA, Chari R, Lam WL, Beer DG. Lockwood WW, et al. Among authors: thu kl. Clin Cancer Res. 2012 Apr 1;18(7):1936-46. doi: 10.1158/1078-0432.CCR-11-1431. Epub 2012 Feb 10. Clin Cancer Res. 2012. PMID: 22328562 Free PMC article.

7

EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation.

Hubaux R, Thu KL, Coe BP, MacAulay C, Lam S, Lam WL. Hubaux R, et al. Among authors: thu kl. J Thorac Oncol. 2013 Aug;8(8):1102-6. doi: 10.1097/JTO.0b013e318298762f. J Thorac Oncol. 2013. PMID: 23857401 Free PMC article.

8

Methylation analysis by DNA immunoprecipitation.

Thu KL, Pikor LA, Kennett JY, Alvarez CE, Lam WL. Thu KL, et al. J Cell Physiol. 2010 Mar;222(3):522-31. doi: 10.1002/jcp.22009. J Cell Physiol. 2010. PMID: 20020444 Review.

9

The detection and implication of genome instability in cancer.

Pikor L, Thu K, Vucic E, Lam W. Pikor L, et al. Cancer Metastasis Rev. 2013 Dec;32(3-4):341-52. doi: 10.1007/s10555-013-9429-5. Cancer Metastasis Rev. 2013. PMID: 23633034 Free PMC article. Review.

10

SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling.

Thu KL, Radulovich N, Becker-Santos DD, Pikor LA, Pusic A, Lockwood WW, Lam WL, Tsao MS. Thu KL, et al. Oncogene. 2014 Jan 16;33(3):279-88. doi: 10.1038/onc.2012.595. Epub 2013 Jan 14. Oncogene. 2014. PMID: 23318427

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page